SCYX PRESS-RELEASE SEC Filing Analysis

Latest settled — T+5d

SCYX ▼ -12.18% at T+5d

SHORT call ✓ call won +12.18% · α vs SPY +12.26% · entry $0.7800 → $0.6850

Next anchor: T+20d due 18h ago

Last close $4.45 (close Jun 8) · -470.51% from $0.7800 entry (call sign-flipped)

Entry anchored
May 11, 03:59 PM ET
via Databento tick

T+1d

0.00%

call 0.00% · α +0.54%

$0.7800

settled 29d ago

T+5d

-12.18%

call +12.18% · α +12.26%

$0.6850

settled 23d ago

T+20d

—

call — · α —

—

due 18h ago

T+60d

—

call — · α —

—

in 8w

Price Chart

Loading chart...

Executive Summary

SCYNEXIS reported Q1 2026 results with a GAAP net loss of $0.42 per share, significantly wider than the consensus estimate of -$0.12, driven by a $8.0M IPR&D charge for the SCY-770 acquisition and a $5.2M warrant liability fair value adjustment. The company completed a $37.2M private placement and ended the quarter with $72.4M in cash, extending its runway to mid-2029, but the core operating loss more than doubled year-over-year with no revenue.

Actionable Insight

The significant EPS miss and widening operating losses are concerning, but the $72.4M cash runway to mid-2029 and upcoming SCY-770 Phase 2 catalyst in Q4 2026 provide a long development horizon. Monitor for topline Phase 1 IV data for SCY-247 in Q3 2026 and any GSK Brexafemme relaunch milestones that could trigger revenue.

Key Facts

GAAP net loss per share of -$0.42 vs consensus of -$0.12 (250% miss)
Net loss of $21.3M vs $5.4M in Q1 2025, driven by $8.0M IPR&D charge for SCY-770 acquisition and $5.2M warrant liability adjustment
Revenue was $0 vs $0.3M in Q1 2025 (no license revenue recognized)
Completed $37.2M private placement on April 1, 2026, with potential for additional $52.2M from warrant exercises
Cash, cash equivalents and investments of $72.4M at March 31, 2026, extending cash runway to mid-2029
GSK committed to Brexafemme relaunch with potential up to $146M in annual net sales milestones
Phase 2 proof-of-concept study for SCY-770 in ADPKD expected to begin Q4 2026 with early efficacy readout in H2 2027

Financial Impact

Net loss widened to $21.3M from $5.4M YoY; EPS miss of -$0.42 vs -$0.12 consensus; cash position $72.4M post-offering

epsnet incomerevenuecash

Risk Factors

No near-term revenue visibility; operating losses expected to continue
SCY-770 Phase 2 proof-of-concept study carries clinical and regulatory risk
Warrant liability fair value adjustment creates earnings volatility tied to stock price
Dilution risk from potential full exercise of $52.2M in warrants

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Analyst Consensus

89% bullish (9 analysts)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3292371

5 reports for SCYX

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for SCYX — sortable, filterable
	Type				Now
May 22, 2026 18d ago	8-K NEUTRAL ★ 4/10	$5.45 $5.33	▼ −2.17%	▼ −3.25%	$4.45 (−18.32%)
May 11, 2026 29d ago	Press Release BEARISH ★ 7/10	$0.7800 $0.6850	▲ +12.18%	▲ +12.26%	$4.45 (−470.51%)
Apr 20, 2026 7w ago	8-K NEUTRAL ★ 3/10	$1.06 $0.9860	▼ −6.98%	▼ −8.06%	$4.45 (+319.81%)
Mar 31, 2026 10w ago	Press Release BULLISH ★ 7/10	$0.9170 $0.9960	▲ +8.62%	▲ +4.67%	$4.45 (+385.28%)
Mar 4, 2026 13w ago	Press Release BULLISH ★ 8/10	$6.34 $7.12	▲ +12.34%	▲ +14.58%	$4.45 (−29.81%)

US Market Status

Market Closed — Opens in 7h 8m

Related Tickers

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access